Table 2.

Characteristics of patients at the end of treatment.

	Leuprolide (N = 41)	Triptorelin (N = 23)	p-value
Values at the end of treatment
Age (years); [median (Q1–Q3)]	10.2 (9.8–10.4)	10.1 (9.8–10.3)	0.353
Weight (kg); [median (Q1–Q3)]	41.5 (35.5–43.8)	40.6 (35.0–46.3)	0.690
Height (cm); [median (Q1–Q3)]	145.7 (138.0–148.6)	142.8 (135.1–149.6)	0.298
PAH (cm); [median (Q1–Q3)]	156.5 (153.7–160.7)	158.2 (151.8–163.7)	0.705
Bone age (years); [median (Q1–Q3)]	11.6 (10.9–12.0)	12.3 (11.0–12.5)	0.077
Duration of therapy (days) [median (Q1–Q3)]	971 (790–1,171)	792 (760–1,003)	0.001
Pubic hair; [N (%)]
Ph 1	13 (31.7%)	7 (30.4%)	0.554
Ph 2	23 (56.1%)	15 (65.2%)
Ph 3	5 (12.2%)	1 (4.3%)
Breast growth; [N (%)]
B1	5 (12.2%)	0	0.206
B2	25 (61.0%)	15 (65.2%)
B3	11 (26.8%)	8 (34.8%)
Absolute change
Weight (kg); [median (Q1–Q3)]	12.0 (9.0–15.7)	10.5 (7.8–14.0)	0.203
Height (cm); [median (Q1–Q3)]	15.6 (12.7–16.8)	16.1 (12.0–19.4)	0.542
PAH (cm); [median (Q1–Q3)]	5.3 (1.4–9.9)	4.2 (3.5–9.8)	0.908
Bone age (years); [median (Q1–Q3)]	2.0 (1.4–2.5)	1.8 (1.5–2.0)	0.308